| ONCO | 8-K | bearish | 8/10 | Onconetix entered into two agreements on July 28, 2026: (1) a securities purchase agreement to sell 37,812 shares of Ser | Jul 29, 2026 |
| ELAB | PRESS-RELEASE | neutral | 3/10 | PMGC Holdings confirms compliance with Nasdaq's new MVLS listing requirement as of July 29, 2026, and is working to corr | Jul 29, 2026 |
| ENTX | PRESS-RELEASE | neutral | 5/10 | No summary provided | Jul 29, 2026 |
| BSEM | S-1 | bearish | 8/10 | BioStem Technologies filed an S-1 registration statement for the resale of up to 3,571,429 shares by a single selling st | Jul 29, 2026 |
| RDY | 6-K | neutral | 4/10 | Dr. Reddy's disclosed that the USFDA completed a 10-day Pre-Approval Inspection (PAI) and GMP inspection at its FTO-SEZ | Jul 29, 2026 |
| ABCL | 8-K | bullish | 6/10 | AbCellera announced a collaboration with Vertex Pharmaceuticals to discover and develop multispecific T-cell engagers (T | Jul 29, 2026 |
| XRTX | 6-K | neutral | 2/10 | XORTX Therapeutics announced the appointment of Depesh Narotam as an independent director effective July 27, 2026. Mr. N | Jul 29, 2026 |
| ETON | 8-K | bullish | 5/10 | Eton Pharmaceuticals submitted a Prior Approval Supplement (PAS) to the FDA seeking to expand the label of KHINDIVI (hyd | Jul 29, 2026 |
| ROIV | DEFA14A | neutral | 3/10 | Roivant Sciences filed a DEFA14A (definitive additional proxy soliciting materials) on July 29, 2026. The filing is mark | Jul 29, 2026 |
| QURE | 8-K | bullish | 8/10 | uniQure reported Q2 2026 results with a net loss of $1.22 per share, significantly missing the $-0.71 consensus estimate | Jul 29, 2026 |
| SYBX | 425, 8-K | bearish | 7/10 | Synlogic (SYBX) has entered into a definitive merger agreement with Caldera Therapeutics, a private biotech, via a rever | Jul 29, 2026 |
| ANIK | 8-K | bullish | 8/10 | Anika Therapeutics reported a transformative Q2 2026 beat, with GAAP EPS of $0.24 (vs $0.03 consensus) and revenue of $3 | Jul 29, 2026 |
| IONS | 8-K | neutral | 5/10 | Ionis reported Q2 2026 total revenue of $268M, up 56% YoY excluding a one-time 2025 sapablursen payment, but GAAP net lo | Jul 29, 2026 |
| ALVO | 6-K | bullish | 7/10 | Alvotech announced the FDA closed its May 2026 inspection of its Reykjavik manufacturing facility with a Voluntary Actio | Jul 29, 2026 |
| MBRX | S-1 | bearish | 6/10 | Moleculin Biotech filed an S-1 for a best-efforts offering of up to 4,566,210 common shares (or pre-funded warrants in l | Jul 29, 2026 |
| ENLV | 6-K | neutral | 3/10 | Enlivex filed a 6-K announcing a management webinar on July 30, 2026, to discuss its recently completed private placemen | Jul 29, 2026 |
| SPRC | 6-K | neutral | 5/10 | No summary provided | Jul 29, 2026 |
| HCWB | PRESS-RELEASE | bearish | 6/10 | HCW Biologics priced a $1.6M private placement offering involving insider participation (CEO, Chairman, SVP), issuing 21 | Jul 29, 2026 |
| PLSE | 8-K | bullish | 5/10 | Pulse Biosciences announced it has surpassed the enrollment midpoint of its NANOPULSE-AF pivotal IDE study evaluating th | Jul 29, 2026 |
| SPRC | PRESS-RELEASE | neutral | 3/10 | SciSparc's majority-owned subsidiary NeuroThera announced successful internal validation of a proprietary quantum sampli | Jul 29, 2026 |
| FOXO | 8-K | bullish | 5/10 | FOXO Technologies' subsidiary Vector BioSource has entered a definitive agreement to acquire four U.S.-based blood colle | Jul 29, 2026 |
| LQDA | PRESS-RELEASE | neutral | 1/10 | Liquidia Technologies, Inc. announced it will report its Q2 2026 results on August 12, 2026. | Jul 29, 2026 |
| RNXT | PRESS-RELEASE | neutral | 1/10 | RenovoRx, Inc. announced it will host a conference call on August 12 to discuss its Q2 2026 results. | Jul 29, 2026 |
| FLNA | 8-K | neutral | 3/10 | Filana Therapeutics reported Q2 2026 results with a net loss of $8.6M ($0.18 per share), improving from $44.2M ($0.92) i | Jul 29, 2026 |
| TOMZ | 8-K | bullish | 5/10 | TOMI Environmental Solutions reaffirmed its $12 million revenue guidance for fiscal 2026, citing strong first-half trend | Jul 29, 2026 |
| LBRX | 8-K | mixed | 6/10 | LB Pharmaceuticals announced a $150M private placement of 3,577,560 shares of common stock at $34.94/share and pre-funde | Jul 29, 2026 |
| PCSA | 8-K | mixed | 6/10 | Processa Pharmaceuticals (PCSA) has entered into a definitive merger agreement to acquire Vidya Therapeutics in a revers | Jul 29, 2026 |
| TEVA | 8-K | mixed | 5/10 | Teva reported Q2 2026 revenue of $4.14B (-1% YoY) and non-GAAP EPS of $0.02, both below consensus ($0.05). The headline | Jul 29, 2026 |
| MNKD | PRESS-RELEASE | bullish | 6/10 | MannKind announced positive topline safety and tolerability results from its Phase 1b INFLO-1 study of nintedanib DPI (M | Jul 29, 2026 |
| ETON | PRESS-RELEASE | bullish | 5/10 | Eton Pharmaceuticals submitted a Prior Approval Supplement (PAS) to the FDA seeking to expand KHINDIVI (hydrocortisone) | Jul 29, 2026 |
